A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

Name: A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
Published: 2025
License: Public Domain

Regeneron Pharmaceuticals · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

retinal vasculitis, anti-vascular endothelial growth factor, aflibercept, neovascular age-related macular degeneration (namd), diabetic macular edema (dme), diabetic retinopathy (dr) without macular edema (me), diabetic retinopathy (dr) with macular edema (me), observational

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

Related documents